Jerusalem, 19 November, 2025 (TPS-IL) — Rafa Laboratories, a Jerusalem-based developer of biodefense and emergency medical solutions, has been awarded a contract worth up to $186 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to advance a new intramuscular formulation of tranexamic acid (TXA). The therapy is designed for rapid, prehospital treatment of life-threatening bleeding, addressing a critical need in trauma and mass-casualty settings.
Rafa said the version, which is injected directly into the muscle, could simplify administration compared to current intravenous TXA and may be paired with an autoinjector.
The deal marks Rafa’s second major collaboration with BARDA.